Tociliuzumab vs placebo or usual care: All‐cause mortality D28
Tociliuzumab leads to lower all‐cause mortality D28 compared with standard care/placebo (high certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Tociliuzumab vs standard care/placebo All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19 Tociliuzumab leads to lower all‐cause mortality D28 compared with standard care/placebo (high certainty). Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane Headline outcomes only | RR 0.88 [0.81, 0.94] | 18 studies · 7428 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.